-- The euro area's industrial producer prices climbed 3.4% month over month in March, following a revised 0.6% drop in February, according to Eurostat data published Wednesday.
Analysts expected a 3.3% increase for the month.
On a yearly basis, producer prices rose 2.1%, against the 3% fall earlier and the consensus of a 1.8% increase.
SSY Group's (HKG:2005) full-range C-reactive and Serum Amyloid A/C-reactive protein test kits obtained medical device registration certificates from the Hebei Provincial Drug Administration of China, according to a Wednesday Hong Kong bourse filing.The kits are used for in vitro quantitative detection of C-reactive protein and serum amyloid A levels in human serum, plasma, or whole blood samples.
Coforge (NSE:COFORGE, BOM:532541) has an average rating of overweight and mean price target of 1,658.15 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Smith & Nephew (SN) posted Q1 2026 revenue of USD1,501M, in line with consensus, representing underlying growth of 3.1% (or 4.4% on an adjusted daily sales basis) but decelerating sequentially across all segments. Orthopaedics slowed to +0.8% (vs. Q4's +7.9%) due to U.S. Knee Implants weakness, while Sports Medicine & ENT remained solid at +6.7%. SN announced a new USD500M share buyback to be completed within the next 12 months and reaffirmed 2026 guidance of 6% underlying revenue growth and USD1.3B trading profit. The 2026 guidance for reported revenue guidance of 7.7% is above the current S&P Capital IQ consensus estimate of around 6.6%. We expect upcoming launches and continued execution of the new RISE strategy to underpin growth momentum. That said, execution on U.S. Knee Implants remains critical to monitor. In our view, the planned Q3 2026 launch of the cementless version of the LANDMARK Knee System represents an important catalyst to address persistent challenges in the Knee business.